Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today announced that President and Chief Executive...
--Retrospective analyses of the Phase 3 SIMPLIFY studies demonstrate safety and activity profile are not impacted by baseline platelet count-- VANCOUVER, BC, Dec. 7, 2020 /CNW/ - Sierra Oncology,...
--Momelotinib demonstrates robust overall survival in both JAKi-naïve and patients previously treated with ruxolitinib-- VANCOUVER, BC, Dec. 5, 2020 /CNW/ - Sierra Oncology, Inc. (SRRA), a...
